Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Haran Schlamm

Rancho Santa Fe, CA Medical Doctor

CMS profile 1311223

Po Box 1254, Rancho Santa Fe, CA 92067

Open in the dashboard

General payments

$130,356

37 records reported · program years 2019–2024

Research payments

$3,200

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Haran Schlamm of Rancho Santa Fe, CA is reported in the CMS Open Payments database as having received $130,356 across 37 general payments and $3,200 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $22,960 5
2023 General $37,240 11
2022 General $26,880 12
2022 Research $3,200 1
2021 General $28,576 6
2020 General $8,400 1
2019 General $6,300 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Haran Schlamm
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to Haran Schlamm were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year Haran Schlamm California median Middle half National median
2019 $6,300 $161 $50–$652 $163
2020 $8,400 $114 $34–$392 $114
2021 $28,576 $137 $41–$509 $132
2022 $26,880 $152 $48–$573 $149
2023 $37,240 $162 $50–$581 $160
2024 $22,960 $162 $52–$583 $164
2025 $0 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $130,356 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $122,640 36 payments
  2. Acquisitions $7,716 1 payment
Products named General payments · program years 2019–2024
  1. ERAXIS $14,700 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Pfizer Inc. $3,200 1 payment

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record